PTE provisions relating to pharmaceutical products in Australia in comparison with European SPC and USA PTE

Janodia, Manthan D (2015) PTE provisions relating to pharmaceutical products in Australia in comparison with European SPC and USA PTE. Journal of Intellectual Property Rights, 20 (3). pp. 147-154.

[img] PDF
Published Patent Term Extension provisions in Australia IPR-193.pdf - Published Version
Restricted to Registered users only

Download (218kB) | Request a copy

Abstract

Pharmaceutical products in Australia can win up to five years of Patent Term Extension (PTE). This article reviews Australian PTE Law and its relationship with regulatory pathway for approving medicinal products. The article describes recent PTE cases involving pharmaceutical products and analyses how effective these PTE provisions are in Australia. Finally, it compares PTE provisions in Australia with European SPC (Supplementary Protection Certificate) and USA PTE Provisions.

Item Type: Article
Uncontrolled Keywords: TGA; ARTG; section 223; escitalopram; lohman.
Subjects: Pharmacy > MCOPS Manipal > Pharmacy Management
Depositing User: KMC Manipal
Date Deposited: 17 Jun 2015 05:03
Last Modified: 17 Jun 2015 05:03
URI: http://eprints.manipal.edu/id/eprint/143037

Actions (login required)

View Item View Item